Biotechnology in Pharmacology
A.Y. 2021/2022
Learning objectives
The course is aimed at providing the student with a view of the biotechnological drugs already available for the treatment of various disease, and to provide the basis for the identification of new pharmacological targets and the design of novel biotechnological drugs.
Expected learning outcomes
At the end of the course the student will have a deep knowledge on the biotechnological drugs on the market, and she/he will be able to apply the knowledge to the identification of new targets and the design end evaluation of novel drugs.
Lesson period: Second semester
Assessment methods: Esame
Assessment result: voto verbalizzato in trentesimi
Single course
This course cannot be attended as a single course. Please check our list of single courses to find the ones available for enrolment.
Course syllabus and organization
Single session
Responsible
Lesson period
Second semester
The lessons will be partly live online and partly registered on Microsoft Teams. In both cases, the registration of the lessons will be made available.
The final examination will be online using Microsoft teams.
All the infomration on the course will be posted on ARIEL.
The final examination will be online using Microsoft teams.
All the infomration on the course will be posted on ARIEL.
Course syllabus
The course is structured in two parts
1. Role of biotechnologies in identifying new therapeutic targets: genomics, epigenetic, proteomics, metabolomics, genetic engineering, recombinant protein, oligonucleotides, monoclonal antibodies, vaccines, organoids.
2. Biotechnological drugs.
Pharmacokinetic of biotechnological drugs; drug development; pharmacology of metabolic disorders (dyslipidemia, diabetes, obesity); pharmacology of hemostasis (anticoagulant and antithrombotic drugs); replacement therapy (hormones, enzymes); antiviral therapies; antineoplastic drugs; gene therapy; cell therapy; nanotechnology.
1. Role of biotechnologies in identifying new therapeutic targets: genomics, epigenetic, proteomics, metabolomics, genetic engineering, recombinant protein, oligonucleotides, monoclonal antibodies, vaccines, organoids.
2. Biotechnological drugs.
Pharmacokinetic of biotechnological drugs; drug development; pharmacology of metabolic disorders (dyslipidemia, diabetes, obesity); pharmacology of hemostasis (anticoagulant and antithrombotic drugs); replacement therapy (hormones, enzymes); antiviral therapies; antineoplastic drugs; gene therapy; cell therapy; nanotechnology.
Prerequisites for admission
The student must have knowledge in physiology, biochemistry, and molecular pharmacology (drug interaction with targets).
Teaching methods
Lectures.
Teaching Resources
Vegeto E, Maggi A, Minghetti P "Farmaci Biotecnologici - aspetti farmacologici e clinici", Cea - casa editrice ambrosiana
Ho RJY, Gibaldi M "Biotechnology and Biopharmaceuticals", Wiley-Liss
Ho RJY, Gibaldi M "Biotechnology and Biopharmaceuticals", Wiley-Liss
Assessment methods and Criteria
The final evaluation consists in an oral examination, lasting approximately 30-40 minutes. The student must answer to questions on the topics discussed during the course, being able to comprehend problems associated with biotechnological drugs, and using appropriate language.
Current biotechnology drugs
BIO/14 - PHARMACOLOGY - University credits: 4
Lessons: 32 hours
Professors:
Calabresi Laura, Ossoli Alice Federica
Pharmacological biotechnology
BIO/14 - PHARMACOLOGY - University credits: 4
Lessons: 32 hours
Professor:
Calabrese Francesca
Professor(s)